| Literature DB >> 29136001 |
Batya Elul1,2, Matthew R Lamb1,2, Maria Lahuerta1,2, Fatima Abacassamo3, Laurence Ahoua1, Stephanie A Kujawski2, Maria Tomo3, Ilesh Jani4.
Abstract
BACKGROUND: Concerning gaps in the HIV care continuum compromise individual and population health. We evaluated a combination intervention strategy (CIS) targeting prevalent barriers to timely linkage and sustained retention in HIV care in Mozambique. METHODS ANDEntities:
Mesh:
Substances:
Year: 2017 PMID: 29136001 PMCID: PMC5685437 DOI: 10.1371/journal.pmed.1002433
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Fig 1Flow chart for study participation.
CIS, combination intervention strategy; SOC, standard of care; VCT, voluntary counseling and testing.
Participant characteristics at study enrollment in the 3 study groups (N = 2,004).
| Characteristic | Total | CIS | CIS+ | SOC | |
|---|---|---|---|---|---|
| Maputo | 1,077 (54%) | 396 (53%) | 275 (56%) | 406 (53%) | 0.58 |
| Inhambane | 927 (46%) | 348 (47%) | 218 (44%) | 361 (47%) | |
| 0.50 | |||||
| Female | 1,292 (64%) | 490 (66%) | 319 (65%) | 483 (63%) | |
| Male | 712 (36%) | 254 (34%) | 174 (35%) | 284 (37%) | |
| 34.2 (9.6) | 34.9 (9.8) | 33.8 (9.9) | 33.8 (9.3) | 0.045 | |
| 18–24 | 265 (13%) | 90 (12%) | 70 (14%) | 105 (14%) | 0.12 |
| 25–39 | 1,233 (62%) | 440 (59%) | 301 (61%) | 492 (64%) | |
| 40–49 | 348 (17%) | 148 (2%) | 87 (18%) | 113 (15%) | |
| 50+ | 158 (8%) | 66 (9%) | 35 (7%) | 57 (7%) | |
| <0.001 | |||||
| Married/partner and living together | 1,068 (53%) | 376 (51%) | 255 (52%) | 437 (57%) | |
| Married/partner, but not living together | 222 (11%) | 101 (14%) | 86 (17%) | 35 (5%) | |
| Single | 713 (36%) | 266 (36%) | 152 (31%) | 295 (38%) | |
| Missing/refused | 1 (0%) | 1 (0%) | 0 (0%) | 0 (0%) | |
| 0.003 | |||||
| None | 164 (8%) | 59 (8%) | 33 (7%) | 72 (9%) | |
| Primary | 1,149 (57%) | 442 (59%) | 256 (52%) | 451 (59%) | |
| Secondary | 471 (24%) | 164 (22%) | 130 (26%) | 177 (23%) | |
| Above secondary | 219 (11%) | 78 (1%) | 74 (15%) | 67 (9%) | |
| Missing/refused | 1 (0%) | 1 (0%) | 0 (0%) | 0 (9%) | |
| 0.46 | |||||
| Employed | 1,473 (74%) | 537 (72%) | 361 (73%) | 575 (75%) | |
| Unemployed | 531 (26%) | 207 (28%) | 132 (27%) | 192 (25%) | |
| <0.001 | |||||
| ≤1,500 meticais | 871 (43%) | 342 (46%) | 165 (33%) | 364 (47%) | |
| >1,500 meticais | 936 (47%) | 343 (46%) | 271 (55%) | 322 (42%) | |
| Missing/refused | 197 (1%) | 59 (8%) | 57 (12%) | 81 (11%) | |
| 0.28 | |||||
| Yes | 550 (27%) | 187 (25%) | 144 (29%) | 219 (29%) | |
| No | 913 (46%) | 361 (49%) | 219 (44%) | 333 (43%) | |
| Don’t know | 539 (27%) | 196 (26%) | 130 (26%) | 213 (28%) | |
| Missing/refused | 2 (0%) | 0 (0%) | 0 (0%) | 2 (0%) |
Data given as N (percent).
CIS, combination intervention strategy; SOC, standard of care.
Linkage to and retention in HIV care: CIS versus SOC and CIS+ versus CIS.
| Category | Outcome | CIS | CIS+ | SOC | RR | aRR | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent | Percent | Percent | CIS versus SOC | CIS+ versus CIS | CIS versus SOC | CIS+ versus CIS | |||||
| At diagnosing facility | Linked to care within 1 month of diagnosis and retained 12 months after diagnosis | 425 | 57% | 273 | 55% | 268 | 35% | 1.58 (1.05–2.39) | 0.96 (0.81–1.16) | 1.55 (1.07–2.25) | 0.94 (0.76–1.18) |
| At any health facility | Linked to care within 1 month of diagnosis and retained 12 months after diagnosis | 547 | 74% | 360 | 73% | 363 | 47% | 1.47 (1.08–2.01) | 0.98 (0.85–1.15) | 1.46 (1.05–2.04) | 0.96 (0.83–1.11) |
| Linkage at diagnosing facility | Same day as HIV test | 659 | 89% | 457 | 93% | 120 | 16% | 9.13 (1.65–50.40) | 1.04 (0.92–1.20) | N/A | |
| Within 1 week of HIV test | 678 | 91% | 461 | 94% | 349 | 46% | 2.43 (0.70–8.41) | 1.03 (0.91–1.16) | N/A | ||
| Within 1 month of HIV test | 703 | 94% | 467 | 95% | 482 | 63% | 1.48 (0.93–2.35) | 1.00 (0.89–1.13) | N/A | ||
| Within 12 months of HIV test | 716 | 96% | 467 | 95% | 592 | 77% | 1.23 (1.03–1.48) | 0.98 (0.87–1.11) | N/A | ||
| Retention at diagnosing facility | 6 months after diagnosis | 462 | 62% | 322 | 65% | 405 | 53% | 1.18 (1.00–1.39) | 1.05 (0.88–1.26) | N/A | |
| 12 months after diagnosis | 435 | 58% | 273 | 55% | 341 | 44% | 1.32 (1.12–1.54) | 0.95 (0.79–1.13) | N/A | ||
1RR accounts for clustering within sites using random-intercept log-Poisson regression with empirical standard error estimates.
2aRR adjusts for patient-level differences using propensity scores.
aRR, adjusted relative risk; CIS, combination intervention strategy; N/A, not applicable; RR, relative risk; SOC, standard of care.
Fig 2Relative risk of the CIS compared to the SOC on the primary outcome at the diagnosing health facility by patient characteristics.
a Fifteen patients with missing information were excluded from this estimate. A description of the variables examined and categories used are provided in the Methods section.
ART determination and initiation, disease progression, and death: CIS versus SOC and CIS+ versus CIS.
| Outcome | CIS | CIS+ | SOC | RR | ||||
|---|---|---|---|---|---|---|---|---|
| Percent | Percent | Percent | CIS versus SOC | CIS+ versus CIS | ||||
| ART eligibility assessed | 744 | 100% | 493 | 100% | 590 | 77% | 1.29 (1.08–1.54) | 1.00 (0.89–1.12) |
| Identified as ART eligible | 557 | 75% | 372 | 75% | 464 | 60% | 1.24 (1.07–1.43) | 1.01 (0.85–1.19) |
| Initiated ART | 484 | 65% | 332 | 67% | 416 | 54% | 1.20 (1.00–1.43) | 1.03 (0.88–1.22) |
| New WHO stage 3/4 or hospitalization | 7 | 1% | 3 | 1% | 23 | 3% | 0.38 (0.07–2.03) | 0.65 (0.12–3.64) |
| Death within 12 months | 46 | 6% | 27 | 5% | 54 | 7% | 0.87 (0.40–1.91) | 0.88 (0.45–1.74) |
| Death before ART initiation | 22 | 3% | 5 | 1% | 29 | 4% | 0.78 (0.46–1.32) | 0.34 (0.09–1.29) |
| Death after ART initiation | 24 | 3% | 22 | 4% | 25 | 3% | 0.96 (0.26–3.48) | 1.38 (0.62–3.07) |
1RR accounts for clustering within sites using random-intercept log-Poisson regression with empirical standard error estimates.
ART, antiretroviral therapy; CIS, combination intervention strategy; RR, relative risk; SOC, standard of care.